Monograph
M03BA03 - Methocarbamol |
Propably not porphyrinogenic |
PNP |
Rationale
Methocarbamol does not show potential for interaction with CYP enzymes, and no porphyrinogenic effects have been identified.
Chemical description
Carbamatic acid ester
Therapeutic characteristics
Methocarbamol is a centrally acting muscle relaxant used in the treatment of musculoskeletal pain. It is administered orally or intravenously, and has a half-life of about 2 hours (SPC).
Metabolism and pharmacokinetics
Methocarbamol is metabolised in the liver, but data on the involvement of CYP enzymes are lacking (SPC, DrugBank). Methocarbamol did not show any potential for significant interactions with CYP3A4, CYP2C8, CYP2B6 or CYP2D6 in an in vitro study (Moody 2018).
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Dolirobax · Molitrem · Robaxin 
Methocarbamol · Robaxin 750 
Ortoton 
Methocarbamol 
Methocarbamol
© NAPOS 2025